



2 September 2024

Tristel plc
("Tristel" or the "Company")

Confirmation of CEO Transition and Directorate Change

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, confirms that Matt Sassone has today assumed his position of CEO of Tristel, following Paul Swinney's retirement, as previously announced on [10 June 2024](#).

The Company also announces that Bart Leemans will step down from the Tristel Board as an Executive Director. He will remain with the business and continue to focus his efforts on the French market in his capacity as Managing Director, Tristel SAS. There are no current plans to replace Bart on the Tristel Board.

Bart was appointed in November 2018 following Tristel's acquisition of his business, the Ecomed Group, the Company's then distributor in Belgium, the Netherlands and France. The French market continues to represent significant untapped growth potential for the Company; sales in France during the year ended 30 June 2024 were £3.0 million, approximately 7% of the Group's total of £41.9 million, compared with 13% of Group sales generated in Germany and 39% in the UK.

Bruno Holthof, Chair of Tristel, commented: *"I would like to welcome Matt to our Company, and also thank Bart for his contribution to the Board during his tenure. He has brought with him great entrepreneurial spirit and drive and I am pleased that he will continue to contribute to the growth of the business through dedicating his efforts to the French market."*

For further information please contact:

Tristel plc

Matt Sassone, Chief Executive Officer
Liz Dixon, Chief Financial Officer

Via Walbrook PR
www.investors.tristel.com

Walbrook PR Ltd

Paul McManus
Charlotte Edgar

Tel: 020 7933 8780 or tristel@walbrookpr.com
Mob: 07980 541 893
Mob: 07884 664 686

Cavendish Capital Markets Limited

Geoff Nash, Camilla Hume/Trisyia Jamaludin (Corporate Finance)
Sunila de Silva (Corporate Broking)

Tel: 020 7220 0500

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the [Tristel](#) brand, and under the [Cache](#) brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>.